Form 4: Sarepta Therapeutics Director Acquires Shares and Stock Options
SEC Form 4 Filing
Director Deirdre P. Connelly reports acquisition of Sarepta Therapeutics stock and stock options.
Summary
- On March 10, 2025, Deirdre P. Connelly, a director of Sarepta Therapeutics, acquired 2,383 shares of common stock through restricted stock units (RSUs).
- These RSUs will vest in full on March 10, 2026.
- Connelly also acquired stock options for 4,792 shares of common stock with an exercise price of $99.69, exercisable from March 10, 2026, to March 10, 2035.
- Following these transactions, Connelly directly owns 5,225 shares of Sarepta Therapeutics common stock and 4,792 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. It reflects insider confidence but is a routine transaction.
Positives
- The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company insiders, such as directors and officers.
Stakeholder Impact
- The acquisition of shares and stock options by a director may increase investor confidence.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 03/11/2025 | Date of signature on the Form 4 filing. |
| 03/10/2026 | RSUs vest in full and stock options become exercisable. |
| 03/10/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.